1254032-16-0

1254032-16-0 structure
1254032-16-0 structure
  • Name: AR-13503
  • Chemical Name: AR-13503
  • CAS Number: 1254032-16-0
  • Molecular Formula: C19H19N3O2
  • Molecular Weight: 321.37
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage ROCK
  • Create Date: 2023-04-27 14:39:19
  • Modify Date: 2024-01-19 16:30:08
  • AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2].

Name AR-13503
Description AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2].
Related Catalog
In Vitro AR-13503 (16 小时) 抑制人脐静脉内皮细胞 (HUVEC) 管的形成,IC50 为 21 nM[1]。 AR-13503 (400 nM; 5 天) 以剂量依赖的方式减少脉络膜的发芽面积[1]。 AR-13503 (400 nM; 2 周) 以剂量依赖的方式增强猪主要 RPE 屏障功能[1]。
In Vivo AR-13503 (1.25 mg/kg;腹腔注射;每天 1 次,共 5 天) 与 Aflibercept (HY-108801) 有协同作用,显著降低了异常新生血管 (NV) 形成[1]。 Animal Model: Oxygen-induced retinopathy (OIR) mice model (C57BL/6; 7-days-old)[1] Dosage: 1.25 mg/kg Administration: Intraperitoneal injection; once daily for 5 days Result: The combination group had a greater (~75%) reduction in NV than Aflibercept alone (~55%).
References

[1]. Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 205-205.

[2]. Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 200-200.

Molecular Formula C19H19N3O2
Molecular Weight 321.37
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.